BioHarvest Sciences Inc. Common Stock BHST
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -69.75%
- 1 year
- -82.46%
- Open
- 1.63
- Prev close
- 1.65
- Mkt cap
- 35.59M
- Vol
- 20.81K
- Avg vol
- 38.71K
- EPS
- -0.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.56
- High
- 1.65
- Forward P/E
- 0.00
- Beta
- 1.49
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.70
- 200-d avg
- 4.12
- 1y target
- 14.67
6M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 6 hours ago |
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| RSI: Oversold | Jul 21, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 24, 2026 | 4 months ago |
| RSI: Oversold | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| RSI: Oversold | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| RSI: Oversold | May 8, 2026 | 5 months ago |
Key statistics
- Market cap
- 105.70M
- Enterprise value
- 114.38M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 5.53
- Price / book
- 0.00
- EPS (TTM)
- -1.28
- Beta
- 1.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -84.84%
- Revenue (TTM)
- 19.13M
- Revenue growth
- 119.20%
- Free cash flow
- -5.96M
- Total cash
- 5.17M
- Total debt
- 10.39M
- Return on equity
- -5955.96%
- Shares outstanding
- 17.33M
- Short % of float
- 0.00%
- 50-day average
- 5.70
- 200-day average
- 4.12
Analyst view
Consensus: buy
- Target (low)
- 12.00
- Target (mean)
- 14.67
- Target (high)
- 18.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 25, 2024 | Sep 1, 2024 | -0.05 | -0.16 | -0.11 | -220.00% |
About BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
- Country
- Canada
- Website
- bioharvest.com
News
- BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
- BioHarvest takes second plant-cell asset to commercial readiness
- BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization
- BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
- BioHarvest says its platform can produce target sweetener in Tate & Lyle program
- Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
- BioHarvest Sciences launches buyback of up to 5% of shares
- BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares
- BioHarvest Sciences Announces Share Repurchase Program
- BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
Your note
Sign in to keep a note on BHST — it syncs with the Stock Master app.